Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan STAP Scandal Shakes Status Of Government-Funded Riken Institute

This article was originally published in PharmAsia News

Executive Summary

The scandal evolving in Japan around a controversial stem cell study's groundbreaking conclusions is having a negative impact on Riken, the nearly century-old government-funded research institute.

The scandal evolving in Japan around a controversial stem cell study's groundbreaking conclusions is having a negative impact on Riken, the nearly century-old government-funded research institute. Riken's leadership was closely involved in the studies that led to "stimulus-triggered acquisition of pluripotency" with the acronym, "STAP." Now the institute is split over the work of a 20-something researcher under great pressure to succeed, the rift possibly endangering Riken's attempt to be named a special national research and development corporation. (Click here for more - a subscription may be required)

"Scientific 'Paradise' Shaken By STAP Scandal" - Nikkei (Japan) (4/17/2014)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC086839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel